The use of CGM to identify type 1 diabetic patients with hypoglycemia problems and its impact for avoidance of biochemical hypoglycemia. by Hermanns, Norbert et al.
The use of CGM to identify type 1 diabetic patients with hypoglycemia problems and its impact 
for avoidance of biochemical hypoglycemia
Hermanns N, Kulzer B, Ehrmann D, Haak T
 FIDAM Research Institute Diabetes Academy, Diabetes Center Mergentheim, Bad Mergentheim, Germany
This cross-over study used a CGM system (DexCom SEVEN PLUS CGM). In a rando-
mized order, participants had either no access (CGM blind) or real time access to 
current glucose data (CGM open). One objective was to analyze if type 1 diabetic 
patients with hypoglycemia problems  (one episode requiring third party assis-
tance) could be identified by the use of the blinded CGM data. We also analyzed 
the impact of CGM use on biochemical hypoglycemia. Type 1 diabetic patients 
with hypoglycemia problems had significant longer diabetes duration (17.0 vs 11.0 
yrs.), a higher unawareness score (4.0 vs 2.0) and lower thresholds for detecting 
hypoglycemia (50.0 vs 65.0 mg/dl) than patients without hypoglycemia problems. 
During the blinded CGM phase patients with hypoglycemic  problems  had a signi-
ficant longer duration of low glucose phases 248 vs.  153 minutes per day (p=.037; 
<70 mg/dl) respectively 173 vs 96 minutes per day (p=.041; <60 mg/dl). Area un-
der the receiver operating curve (ROC 0.72 p=.03) indicated a sufficient screening 
performance of the  duration of low glucose periods (< 70 mg/dl) for the identifi-
cation of patients with hypoglycemia problems. A cut-off of 170 minutes per day 
of time spend in the low glucose range had a sensitivity of 75% and a specificity 
of 70.3%; the positive predictive value was 52.9%, the negative predictive value 
was 86.4%. A comparison of blind vs. open CGM showed that time spend in a low 
glucose range could be significantly more reduced in patients with hypoglycemia 
problems than in patients without  hypoglycemia problems during CGM open (< 
60 mg/dl; – 67.8 min per day p=.040; < 50 mg/dl; -50.6 min per day, p=.038; < 40 
mg/dl; -41.4 min. per day,  p=.03). This study shows that CGM has an unused po-
tential for identifying type 1 diabetic patients at risk for hypoglycemia problems in 
clinical practice as well as for avoidance of biochemical hypoglycemia, which plays 
a pivotal role for the development of hypoglycemia associated autonomic failure.
The potential of CGM for the identification of patients with hypoglycemia problems 
and for the avoidance of hypoglycemic episodes is not sufficiently understood. This is 
partly due to the fact that most CGM studies are powered to detect an improvement 
in glycemic control as primary outcome. Besides, patients with hypoglycemia problems 
are often excluded from study participation. This short term pilot study aimed at two 
objectives:
1. to analyze whether CGM data can be used to identify people with type 1 diabetes 
and hypoglycemia problems 
2. to analyze whether people with type 1 diabetes and hypoglycemia problems had 
more benefit from CGM use than people with type 1 diabetes but without hypogly-
cemia problems with regard to the duration of biochemical hypoglycemia
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In this study 40 people with type 1 diabetes took part.
• Sample characteristics are depicted in table 1. People with hypoglycemia problems 
had significant longer diabetes duration, a higher unawareness score and reported 
a significant lower threshold for recognizing hypoglycemia symptoms. Thus, clinical 
characteristics of people with hypoglycemia problems showed expected differen-
ces to people without hypoglycemia problems (table 1).
• In the CGM blind-phase, the wearing time of the sensor was 109 hours. The accu-
racy of the system was in the expectable accuracy range for CGM. Median gluco-
se levels showed a moderate overall hyperglycemia, which fits to the duration of 
eu- and hyperglycemic phases. There was no significant difference between people 
with and without hypoglycemia problems with regard to the variables mentioned 
above (table 2).
• During the CGM blind-phase, CGM-data showed that people with hypoglycemia 
problems spent a significant longer time in the low glucose range than people with 
type 1 diabetes without hypoglycemia problems (figure 1).
• The duration spent in the hypoglycemic glucose range can be used to identify people 
with type 1 diabetes and hypoglycemia problems. The Receiver Operating Charac-
teristics Curve showed a significant better “screening performance” of the duration 
of low glucose phases for the identification of people with hypoglycemia problems 
than a random chance classification. Optical inspection of the ROC suggests a cut-
off point of 170 minutes spent in a hypoglycemic glucose range (< 70 mg/dl) to 
identify people with hypoglycemia problems with an optimal sensitivity (75%) and 
specificity (70.3%). The positive predictive value of 52.9% suggests that every se-
cond patient with a duration of hypoglycemic phases by 170 minutes or more has 
hypoglycemia problems (Figure 2).
• In figure 3 the reduction of time spent in the hypoglycemic range during the CGM 
open-phase compared to CGM blind-phase is shown. People with hypoglycemia pro-
blems could reduce their time spent in the hypoglycemic range significantly more 
than people without hypoglycemia problems.
• The effect sizes for hypoglycemia avoidance in people with diabetes are depicted in 
figure 4. The effect sizes suggest a moderate to large effect of CGM use for avoiding 
biochemical hypoglycemia in people with hypoglycemia problems.
Figure 4:  Effect sizes of CGM use for avoidance of hypoglycemia in people with and and without 
hypoglycemia ± 95% CI
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Figure 1:  Mean duration of hypoglycemic phases per day in people with and without  
hypoglycemia problems ± SEM adjusted for order effects
Figure 2:  Area under the receiver operating characteristics curve for identification of people 
with diabetes and hypoglycemia problems (Area under ROC .72, p=03)
This pilot study showed that CGM has an unused potential for identifying type 1 diabe-
tic patients at risk for hypoglycemia problems in clinical practice. Hypoglycemia associ-
ated autonomic failure (Haaf), exposing patients to more frequent and longer phases 
of hypoglycemia, has emerged as a key factor for the development of hypoglycemia 
problems in people with diabetes. People with type 1 diabetes and hypoglycemia pro-
blems can be identified with satisfactory precision by using CGM. Furthermore, open 
CGM provides current glucose levels and alerts people with diabetes if pre-defined 
hypoglycemic glucose limits are met. These preliminary data suggest that CGM allows 
people with hypoglycemic problems to reduce exposure to hypoglycemic glucose valu-
es more effectively than people without hypoglycemia problems. The observed effect 
sizes are rather large. The obvious limitation of this study is its small sample size and 
short duration. Therefore, trials with larger samples and longer duration are necessary 
to demonstrate the ability of CGM to reduce exposure to hypoglycemia - a key risk fac-
tor for Haaf - in people with type 1 diabetes and hypoglycemia problems.
This cross-over study used the DexCom SEVEN PLUS CGM system. In a randomized or-
der participants had either no access (CGM blind) or real time access to current gluco-
se data (CGM open) and were alerted if glucose fell beneath a lower limit of 80 mg/dl. 
Each of the CGM phases was scheduled for 96 to 120 hours. In this study type 1 diabe-
tes patients with and without hypoglycemia problems were included. Hypoglycemia 
problems were defined as having experienced at least one hypoglycemic episode re-
quiring third party assistance for recovery during the past year. Patients also completed 
the hypoglycemia awareness scale (Clarke et al, Diabetes Care, 18, 1995, 517-522). 
Table 1:  Sample characteristics of the total sample and for people with and without  
hypoglycemia problems. Depicted are median and Inter-Quartil-Range (IQR)
Table 2:  Results of CGM blind-phase of the total sample and for people with and without  
hypoglycemia problems. Depicted are median and IQR
Figure 3:  Mean change in the duration of hypoglycemic phases per day in people with  
and without hypoglycemia problems ± SEM adjusted for order effects
